Summary

The 7 major rhinosinusitis markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.64% during 2024-2034.

The rhinosinusitis market has been comprehensively analyzed in IMARC's new report titled "Rhinosinusitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rhinosinusitis refers to a medical condition in which the paranasal sinuses and the mucous membranes around the nasal passages become infected and inflamed. The disease is characterized by obstruction and/or nasal congestion or a runny nose with discharge that may drain at the back or front of the nose. Depending on its duration, the illness is classified as acute or chronic rhinosinusitis. The common symptoms of this ailment include difficulty breathing, swelling and pain throughout the face, stuffiness, headache, itchy nose, fatigue, discolored or cloudy nasal discharge, decreased sense of smell, persistent cough, etc. Additionally, individuals suffering from rhinosinusitis may experience swelling around the eyes, pus, phlegm, fever, sore throat, etc. The diagnosis of this disease is based on a review of the patient's symptoms and a physical examination with a nasal endoscopy. The healthcare professional may also perform diagnostic procedures, such as a computed tomography (CT) scan that combines X-rays to provide a detailed 3-D image of the affected areas.

The increasing incidences of allergies and bacterial or viral infections, which can irritate the nasal passage, leading to blockages and fluid accumulation, are primarily driving the rhinosinusitis market. In addition to this, the rising prevalence of various risk factors, including a weakened immune system, smoking, structural abnormalities in the nasal cavity, certain comorbid medical conditions, etc., is also bolstering the market growth. Furthermore, the widespread adoption of over-the-counter pain relievers, such as acetaminophen, ibuprofen, aspirin, etc., to help reduce pain and fever associated with the disease is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to launch novel diagnostic tools for early diagnosis of rhinosinusitis and treatment monitoring in patients. This, in turn, is also creating a positive outlook for the market. Moreover, the inflating utilization of topical intranasal therapy, since it can reduce inflammation and correct mucociliary dysfunction, is further propelling the market growth. Besides this, the emerging popularity of allergy shots (immunotherapy), which limit the body's reaction to specific allergens and help treat the symptoms, is expected to drive the rhinosinusitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the rhinosinusitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rhinosinusitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rhinosinusitis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the rhinosinusitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the rhinosinusitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current rhinosinusitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the rhinosinusitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the rhinosinusitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the rhinosinusitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of rhinosinusitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of rhinosinusitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of rhinosinusitis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of rhinosinusitis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with rhinosinusitis across the seven major markets?
What is the size of the rhinosinusitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of rhinosinusitis?
What will be the growth rate of patients across the seven major markets?

Rhinosinusitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for rhinosinusitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rhinosinusitis market?
What are the key regulatory events related to the rhinosinusitis market?
What is the structure of clinical trial landscape by status related to the rhinosinusitis market?
What is the structure of clinical trial landscape by phase related to the rhinosinusitis market?
What is the structure of clinical trial landscape by route of administration related to the rhinosinusitis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Rhinosinusitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Rhinosinusitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Rhinosinusitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Rhinosinusitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Rhinosinusitis - Unmet Needs

10 Rhinosinusitis - Key Endpoints of Treatment

11 Rhinosinusitis - Marketed Products
11.1 List of Rhinosinusitis Marketed Drugs Across the Top 7 Markets
11.1.1 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Rhinosinusitis - Pipeline Drugs
12.1 List of Rhinosinusitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Tezepelumab - Amgen/AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Rimegepant - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CM 326 - KeyMed Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LYR-210 - Lyra Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Rhinosinusitis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Rhinosinusitis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Rhinosinusitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Rhinosinusitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Rhinosinusitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Rhinosinusitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Rhinosinusitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Rhinosinusitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Rhinosinusitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Rhinosinusitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Rhinosinusitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Rhinosinusitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Rhinosinusitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Rhinosinusitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Rhinosinusitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Rhinosinusitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Rhinosinusitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Rhinosinusitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Rhinosinusitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Rhinosinusitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Rhinosinusitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Rhinosinusitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Rhinosinusitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Rhinosinusitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Rhinosinusitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Rhinosinusitis - Access and Reimbursement Overview

16 Rhinosinusitis - Recent Events and Inputs From Key Opinion Leaders

17 Rhinosinusitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Rhinosinusitis Market – Strategic Recommendations

19 Appendix